SCHEDULE: EcoR1 Capital Discloses 5.8% Stake in HilleVax, Inc.

EcoR1 Capital, LLC, along with Oleg Nodelman and EcoR1 Capital Fund Qualified, L.P., has reported beneficial ownership of 5.8% of HilleVax, Inc.'s common stock.

Summary

• EcoR1 Capital, LLC and Oleg Nodelman each beneficially own 2,892,000 shares of HilleVax, Inc. common stock, representing 5.8% of the class.
• EcoR1 Capital Fund Qualified, L.P. beneficially owns 2,709,498 shares, representing 5.4% of the class.
• The percentages are calculated based on 50,141,064 shares of Common Stock outstanding on May 5, 2025, as reported in HilleVax, Inc.'s Form 10-Q for the quarter ended March 31, 2025.
• All reported shares are held with shared voting and shared dispositive power by the respective reporting persons.
• The securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing the control of HilleVax, Inc.

Sentiment

Score: 5

Explanation: The filing is a standard beneficial ownership disclosure (Schedule 13G), which is factual and does not inherently convey positive or negative sentiment regarding the company's performance or prospects. It simply reports a significant ownership stake.

Future Outlook

NA

Industry Context

This filing indicates a significant passive investment by EcoR1 Capital, a healthcare-focused investment firm, in HilleVax, Inc., a biotechnology company. Such disclosures are common for institutional investors crossing beneficial ownership thresholds and typically reflect a long-term investment strategy rather than an immediate operational impact.

Stakeholder Impact

• Shareholders: The disclosure of a significant institutional investor holding over 5% of the common stock may be viewed positively by other shareholders, indicating institutional confidence in the company.

Key Dates

Keywords

HilleVax, EcoR1 Capital, Oleg Nodelman, Beneficial Ownership, Schedule 13G, Common Stock, Investment Adviser, Biotechnology